ANNX - Annexon, Inc.

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on July 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

Jul 16, 2026 12:05 PM • globenewswire.com

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026

BRISBANE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced an oral presentation on the neuroprotective effect of vonaprument at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting being held July 15–18, 2026 in Montréal, Québec, Canada.

Jul 14, 2026 12:05 PM • globenewswire.com

Annexon: Perfect Complement To A Speculative Biotech Portfolio

Annexon remains a high-risk/high-reward Buy, driven by two near-term blockbuster therapies, notably tanruprubart for Guillain-Barré syndrome (GBS). Tanruprubart achieved highly significant Phase 3 results, with a 2.4-fold GBS-DS improvement versus placebo and strong safety, positioning it for standard-of-care status. Regulatory filings are underway: MAA was submitted to EMA, with FDA BLA planned for 2026, supported by ongoing FORWARD and real-world evidence studies.

Jul 14, 2026 01:43 AM • seekingalpha.com

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on June 13, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

Jun 16, 2026 12:05 PM • globenewswire.com

Annexon, Inc. (ANNX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Annexon, Inc. (ANNX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Jun 09, 2026 06:42 AM • seekingalpha.com

Annexon Eyes ‘Win Season' With Q4 Vision Trial Data, GBS Filings Ahead

Annexon NASDAQ: ANNX executives used a Goldman Sachs Healthcare Conference session to outline the company's upcoming clinical and regulatory catalysts, led by pivotal Phase III data expected in the fourth quarter for vonaprument in geographic atrophy, a form of advanced dry age-related macular degeneration.

Jun 09, 2026 05:07 AM • marketbeat.com

Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout

Annexon NASDAQ: ANNX executives outlined a series of expected clinical and regulatory updates across the company's complement-focused pipeline during a session at the Jefferies Conference, highlighting programs in geographic atrophy, Guillain-Barré syndrome and cold agglutinin disease.

Jun 03, 2026 11:07 PM • marketbeat.com

Annexon to Participate in Upcoming June Investor Conferences

BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following June investor conferences:

May 27, 2026 04:00 AM • globenewswire.com

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

May 18, 2026 12:05 PM • globenewswire.com

Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference

Annexon NASDAQ: ANNX President and CEO Doug Love outlined the company's late-stage pipeline and regulatory plans during a presentation at the Bank of America Healthcare Conference, highlighting upcoming data in geographic atrophy and regulatory filings for Guillain-Barré syndrome.

May 14, 2026 12:06 AM • marketbeat.com

Annexon, Inc. (ANNX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Annexon, Inc. (ANNX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

May 13, 2026 01:10 PM • seekingalpha.com

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS

CONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and named in 1916 by French neurologists Georges Guillain, Jean Alexandre Barré, and André Strohl.

May 11, 2026 06:00 AM • globenewswire.com

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA

May 07, 2026 12:01 PM • globenewswire.com

Annexon to Present at the Bank of America Securities Health Care Conference 2026

BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., President and Chief Executive Officer, will present at the Bank of America Securities Health Care Conference 2026 on Wednesday, May 13, 2026 at 11:20 a.m. PT.

May 06, 2026 04:00 AM • globenewswire.com

Annexon CEO Touts “Win Year” 2026 at Needham, Eyes GA Phase III Data and GBS FDA Filing

Annexon (NASDAQ: ANNX) President and CEO Doug Love outlined a series of anticipated clinical and regulatory milestones during the 25th Annual Needham Healthcare Conference, describing 2026 as a "win year" after more than a decade of work developing therapies that target the classical complement pathway. Key milestones highlighted for 2026 Love said the company expects multiple

Apr 16, 2026 11:31 PM • defenseworld.net

Annexon (NASDAQ:ANNX) Shares Down 6.1% – Should You Sell?

Shares of Annexon, Inc. (NASDAQ: ANNX - Get Free Report) traded down 6.1% on Friday. The company traded as low as $5.82 and last traded at $5.7650. 799,310 shares traded hands during trading, a decline of 70% from the average session volume of 2,644,675 shares. The stock had previously closed at $6.14. Wall Street Analysts

Apr 12, 2026 12:10 AM • defenseworld.net

Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference

BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq.

Apr 08, 2026 12:05 PM • globenewswire.com

Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High?

The mean of analysts' price targets for Annexon (ANNX) points to a 165.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Apr 01, 2026 06:55 AM • zacks.com

Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA

Mar 30, 2026 12:01 PM • globenewswire.com

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on March 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

Mar 16, 2026 12:05 PM • globenewswire.com

H.C. Wainwright Reiterates Buy Rating on Annexon Biosciences (ANNX)

$14.00 (was $5.80)

Andrew Fein · H.C. Wainwright

Jul 20, 2026 06:50 AM • StreetInsider

Annexon initiated with a Neutral at Goldman Sachs

$7.00 (was $5.68)

Goldman Sachs

May 12, 2026 05:12 AM • TheFly

Annexon initiated with a Buy at Chardan

$16.00 (was $5.19)

Daniil Gataulin · Chardan Capital

Dec 23, 2025 04:30 AM • TheFly

Annexon Biosciences (ANNX) PT Raised to $14 at Wells Fargo

$14.00 (was $5.99)

Derek Archila · Wells Fargo

Jun 05, 2024 01:54 AM • StreetInsider

Annexon Biosciences (ANNX) PT Lowered to $10 at Wells Fargo

$10.00 (was $4.82)

Derek Archila · Wells Fargo

May 15, 2024 01:14 AM • StreetInsider

Wells Fargo Adds Annexon Biosciences (ANNX) to Q2 '24 Tactical Idea List

$12.00 (was $7.17)

Derek Archila · Wells Fargo

Apr 01, 2024 01:50 AM • StreetInsider